Summarized by Masters of Longevity from Longevity Technology.
Solengepras in Parkinson’s — a news article previewing trial results of an oral adjunctive therapy and what readers can expect from the study coverage.
Key Takeaways
- Solengepras 150 mg reduced average daily OFF time by 0.61 hours versus placebo at Week 12 with p=0.0350.
- Treatment increased ON time without troublesome dyskinesia by 0.60 hours versus placebo with p=0.0468.
- ARISE randomized 341 participants across two doses and placebo with 91% trial completion and results presented at MDS 2026.
